Granules India Implements Digital Overhaul Following FDA Warning Over Manufacturing Violations
核心洞察
Granules India is digitizing manufacturing records and increasing facility oversight after the FDA flagged violations in good manufacturing practices at its largest plant in Telangana.
The company, one of the world's largest paracetamol manufacturers, failed to establish adequate equipment cleaning procedures and had torn data records found in plastic waste bags.
The drugmaker is implementing automation of data collection and increasing gemba walks across its 10 manufacturing facilities to prevent future regulatory issues.
Granules India, one of the world's largest paracetamol manufacturers, is implementing comprehensive digital reforms and enhanced oversight measures following a U.S. Food and Drug Administration (搜索) warning over manufacturing violations at its largest facility. The company derives a bulk of its revenue from the U.S. market and is a major player in the active pharmaceutical ingredients sector.
FDA Violations Prompt Regulatory Response
The FDA flagged violations in good manufacturing practices, equipment cleaning, and contamination controls at Granules' plant in the southern Indian state of Telangana last year. According to the regulatory findings, the firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment. In a particularly concerning discovery, FDA inspectors found a large amount of torn data records in 15 plastic waste bags.
While the warning did not halt production at the facility, it could temporarily affect FDA approval of new products manufactured at the site. This regulatory action highlights the ongoing scrutiny faced by Indian pharmaceutical manufacturers in maintaining compliance with U.S. standards.
Digital Transformation Initiative
Executive Director Priyanka Chigurupati outlined the company's response strategy in a recent interview with Reuters. "We expect the FDA to come anytime," Chigurupati said, emphasizing the urgency of the remediation efforts.
The drugmaker will move its operations logbooks, batch manufacturing records, and badge cards online over the next few months to reduce data-related regulatory risks. This digitization initiative represents a fundamental shift in how the company manages critical manufacturing documentation.
Enhanced Manufacturing Oversight
Granules has increased the frequency of gemba walks, where managers observe manufacturing practices to identify bottlenecks, as part of its standard operating procedure at the facility. "So whenever there's an issue, we stop and don't move forward," Chigurupati explained, adding that this approach will help avoid issues with product quality.
The company operates 10 manufacturing plants globally, with seven located in India, two in the U.S., and one in Europe. The enhanced oversight measures will be implemented across all facilities to ensure consistent compliance standards.
Investment in Automation and Controls
The firm will focus on implementing automation of data collection and tightening controls across facilities, with the company setting aside a "certain amount" of capital expenditure for these improvements, though specific financial details were not disclosed.
"We hadn't thought about it (automation and controls) earlier, but now we are, and it's high time we did, so we're really adapting and adopting those practices," Chigurupati said, acknowledging the company's shift toward more sophisticated manufacturing systems.
The comprehensive response demonstrates Granules India's commitment to addressing regulatory concerns while maintaining its position as a key supplier in the global pharmaceutical ingredients market.